Panel IDs Hyperglycemia Management Options For Novartis’ Signifor
FDA’s Endocrinologic and Metabolic Drugs Advisory Committee suggests aggressive monitoring and limitations for who should take pasireotide, which the panel backed unanimously Nov. 7.
You may also be interested in...
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.
Stakeholder meeting will address poor enrollment rates and other issues that undermine the utility of pregnancy registries, as well as the use of alternatives, such as case control studies and claims-based database studies.